• 1
    Honkoop P, De Man RA, Niesters HGM, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 6359.
  • 2
    Song BC, Suh DJ, Lee HC, et al. Hepatitis B antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 8036.
  • 3
    Chan HLY, Wong ML, Hui AY, et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003; 9: 26957.
  • 4
    Chan HLY, Leung NWY, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon alfa-2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 24050.
  • 5
    Janssen HLA, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365: 1239.
  • 6
    Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 268295.
  • 7
    Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999; 19: 15769.
  • 8
    Ma P, Chen D, Pan J, et al. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002; 165: 14851.
  • 9
    Hall SK, Perregaux DG, Gabel CA, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1β gene with secretion of interleukin-1β protein. Arthritis Rheum 2004; 50: 197683.
  • 10
    Pociot F, Molvig J, Wogensen L, et al. A Taq I polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Euro J Clin Invest 1992; 22: 396402.
  • 11
    Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allete 2 (ILRN*2) is associated with enhanced IL-1 beta production in vitro. Scand J Immunol 1998; 47: 1958.
  • 12
    Zhang PA, Li Y, Xu P, et al. Polymorphism of interleukin-1B and interleukin-1 receptor antagonist genes in patients with chronic hepatitis B. World J Gastroenterol 2004; 10: 18269.
  • 13
    Chan HLY, Hui AY, Wong VWS, et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41: 135764.
  • 14
    Loeb KR, Jerome KR, Goddard J, et al. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 2000; 32: 6269.
  • 15
    Chan HLY, Chui AKK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 1827.
  • 16
    El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398402.
  • 17
    Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403404.
  • 18
    Liu K, Muse Spencer. PowerMarker: New Genetic Data Analysis Software, Version 3.23. North Carolina, US: North Carolina State University.
  • 19
    Lok ASF. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992; 10: 4652.
  • 20
    Milich DR, McLachlan A. The nucleocapsid of the hepatitis B virus I both a T-cell-independent and a T cell-dependent antigen. Science 1986; 234: 13981401.
  • 21
    Hsu HY, Chang MH, Hsieh KH, et al. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992; 15: 7706.
  • 22
    Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 6591.
  • 23
    Chan HLY, Tsang SWC, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histologic liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: 40612.
    Direct Link:
  • 24
    Ter Borg F, Ten Kate FJW, Cuypers HTM, et al. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet 1998; 351: 19148.
  • 25
    Perrillo R, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 18694.
  • 26
    Chien RN, Liaw YF, Atkins M, et al. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 7704.
  • 27
    Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viraemia? Hepatology 2001; 34: 10216.
  • 28
    Sung JJY, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 189097.
  • 29
    Werle-Lapostolle B, Vowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 175058.
  • 30
    Zeng ZR, Hu PJ, Hu S, et al. Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut 2003; 52: 16849.
  • 31
    Yeo AET, Tanaka Y, Furuta T. Interleukin 1β gene polymorphism and hepatitis C virus-related hepatocellular carcinoma. Hepatology 2003; 38: 2678.
  • 32
    Wang Y, Kato N, Hoshida Y, et al. Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003; 37: 6571.